analysis of the tumor showed that it was isocitrate dehydrogenase 1 wild type, telomerase reverse transcriptase promoter mutant, epidermal growth factor receptor overexpressed and amplified, and methyl-guanine methyltransferase promoter methylated. Initial treatment course included 6 weeks of concurrent radiation and temozolomide (TMZ) and enrollment in a clinical trial where he received two doses of basiliximab, CD25 monoclonal antibody, and adjuvant TMZ dosed at 200 mg/m 2 (5 days on and 23 days off in 28-day cycle). After the fifth cycle of adjuvant TMZ, he had tumor progression on MRI and underwent re-resection confirming recurrent GBM. He then enrolled in a clinical trial utilizing single-agent pembrolizumab dosed at 200 mg intravenously every 3 weeks. He was chosen for this trial as he was in his first progression of disease, had at least 4 weeks since surgical resection, had previously been treated with radiation and TMZ, and he did not have a diagnosis of immunodeficiency.
For 14 months, he tolerated pembrolizumab well. During month 15, the patient developed arthralgia at the left shoulder with associated decreased range of motion. He reported some mild knee pain and foot discomfort, although this was not interfering with his daily activities. He received a lidocaine injection to his left shoulder that relieved some discomfort, and he subsequently initiated in celecoxib 100 mg orally twice a day because of continued joint pain at his jaw, wrist, fingers, and ankles. This pain and arthralgia, although generalized, remained manageable for 3 months.
In early month 17, he reported worsening pain, particularly to the left shoulder, left knee, bilateral wrists, and ankles. Sports/rehabilitative medicine providers evaluated him and recommended prednisone 50 mg orally daily for 5 days. While this initially mitigated pain and arthralgia, these symptoms returned after therapy concluded. Despite these symptoms, he continued pembrolizumab.
After this initial course of prednisone, pain in the left knee worsened. MRI of the left knee showed evidence of synovial proliferation and thickening consistent with inflammatory arthritis. This prompted a cortisone injection to the knee and a short discontinuation of pembrolizumab. Despite these two interventions, pain and arthralgia persisted. Of note, prior to pembrolizumab therapy, the patient was an avid runner, running up to 10 miles at one time. After 17 months of pembrolizumab, he had challenges with running just 1 mile.
Because of continued joint pain, arthralgia, and decline in exercise ability, he discontinued pembrolizumab. Neuro-oncology providers consulted with the rheumatologist who initiated sulfasalazine, a common disease-modifying drug used in the treatment of rheumatoid arthritis, 500 mg orally twice daily. Unfortunately, the symptoms worsened. The patient attempted further courses of prednisone, nonsteroidal anti-inflammatory agents (NSAIDs), and narcotics, but pain continued and physical function declined. Pain and swelling now involved most joints including the jaw, bilateral knees, feet, ankles, hands, and wrists. He could no longer make a fist and could not type or write.
After laboratory and radiographic evaluation, the rheumatologist diagnosed him with inflammatory arthritis due to pembrolizumab. He started a prolonged prednisone taper, but unfortunately, his pain worsened. His providers stopped the tapering of prednisone and initiated methotrexate (MTX) 2.5 mg daily with folate 1 mg orally daily. After 6 months on MTX and folate, he was able to make a fist with both hands and started swimming for exercise. Given that the pain had not completely resolved, his rheumatologist started adalimumab, a monoclonal antibody that blocks tumor necrosis factor-α and used for rheumatoid arthritis, approximately 5 months after MTX. He is currently in month 10 of MTX and has not required any additional prednisone after tapering off 8 months of daily use. Table 1 elucidates the course of the patient's symptoms and relevant treatment.
It is important to note that despite not being on therapy for his GBM since discontinuation of pembrolizumab on month 15, he continues to have MRI brain with no evidence of tumor recurrence for over 24 months [ Figure 1 ].
disCussion
Immunotherapy, in particular PD-1 checkpoint inhibitors, has revolutionized the treatment in many different types of cancer, and PD-1 inhibition via pembrolizumab is being explored in GBM patients. [3] Commonly seen IrAEs are fatigue, rash, and colitis. [2] Notably, the recent KEYNOTE-28 trial involving single-agent pembrolizumab in recurrent GBM reported common IrAEs that included fatigue, colitis, thyroiditis, and rash. [3] Cancer patients receiving checkpoint inhibitors do report drug-induced arthralgia. The KEYNOTE-087 trial reported that 10% of non-Hodgkin's lymphoma patients receiving pembrolizumab had arthralgia. [4] The KEYNOTE-028 trial using pembrolizumab in mesothelioma noted that 20% had arthralgia. [5] While arthralgia can occur commonly, a systematic review of the literature by Abdel-Rahman et al. [6] revealed that arthritis and musculoskeletal IrAEs are very rare in cancer patients on checkpoint inhibitors.
In a retrospective study of 496 patients with melanoma who received pembrolizumab, eight patients (1.6%) reported arthralgia and noted one patient with synovitis of the wrist and one with exacerbation of psoriatic arthritis. [7] Treatment of these IrAEs included NSAIDs and systemic prednisolone (up to 0.5 mg/kg orally). Unique to our case presented, the patient 
